Role of Atosiban in Recurrent Implantation Failure

Recurrent Implantation Failure Clinical Trial

— RIF  

Official title:

The Value of Atosiban on the Day of Embryo Transfer in Patients With Recurrent Implantation Failure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04118959
• Other study ID #: K.Rageh
• Status: Recruiting
• Start date: October 10, 2019
• Est. completion date: November 25, 2021

Study information

• Verified date: September 2021
• Source: Al Baraka Fertility Hospital
• Contact: Kamal eldin Rageh, M.D.
• Phone: 0097333153871
• Email: dr_kamal_rageh[@]yahoo.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

ET is the final stage of IVF which independently influences the treatment outcome. Successful embryo implantation is dependent on uterine receptivity. Atosiban is a novel class of drug which is effective in priming the uterus for implantation. It reduces uterine contractions and increases endomyometrial perfusion, both of which have potential benefits regarding improved IRs, CPR, and ongoing pregnancy rates. Atosiban has a good embryonic safety profile. It has no systemic toxicity, no mutagenic effects, and no carcinogenic effects

Description:

ET is a critical step of an IVF cycle that merits the utmost attention. Its success depends on the frequency of uterine contractions, the endometrial receptivity and the quality of embryos transferred.

Uterine contractions are the most fundamental constituents of the uterine receptivity. Excessive contractions may decrease the implantation potential of embryos by expelling the embryos from the uterus. Studies have revealed a six-fold increase in uterine contractility in IVF cycles when measured before ET as compared to the condition before ovulation in natural cycles. Excessive manipulation of the cervix such as the use of tenaculum during difficult ET can also trigger uterine contractions, consequently leading to failure of embryo implantation.

IVF success rates have been potentially improved by the use of drugs that inhibit pronounced uterine contractions at the time of ET. Treatment strategies such as the use of beta-agonists or nonsteroidal anti-inflammatory agents for tocolysis have not been beneficial in IVF-ET procedures.

Atosiban is a combined oxytocin/vasopressin V1A antagonist. It functions mainly by blocking oxytocin and vasopressin V1a receptors to decrease the frequency and amplitude of uterine contractions, which enhances implantation and pregnancy rates. RIF remains unexplained in most cases, which results in considerable variation in how RIF is treated and managed. Atosiban competes with oxytocin at oxytocin receptors in endometrial cells and inhibits oxytocin-induced PGF2α release, thus inhibiting uterine contractions and increasing chances of embryo implantation and may add value in improving the outcome in RIF patients.

Recently published studies showed that atosiban inhibits oxytocin-induced PGF2α and uterine contractility, consequently leading to improved IRs. Studies have shown a considerable reduction in the frequency of uterine contractions before and after the administration of atosiban in women undergoing ET.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: November 25, 2021
• Est. primary completion date: November 20, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 22 Years to 40 Years

Eligibility

Inclusion Criteria:

1. Women 22-40 years age

2. Body mass index- 18.5-30 kg/m 2

3. The normal uterine cavity on ultrasound scan

4. At least one good quality embryo present for transfer

5. Endometrium thickness =7.5 mm with endometrial volume 2-2.5 ml and good endometrial and subendometrial vascularity.

Exclusion Criteria:

• 1. Women = 40 years age 2. Uterine abnormalities that can compromise the IRs (e.g., endometrial polyp, fibroids, hydrosalpinx, and adenomyosis) 3. Patients at risk of ovarian hyperstimulation syndrome 4. Patients with a history of hypersensitivity to atosiban 5. Endocrine dysfunction 6. Major organ dysfunction such as liver or kidney failure.

Related Conditions & MeSH terms

• Recurrent Implantation Failure

Locations

Country	Name	City	State
Bahrain	Al-BARAKA FERTILITY HOSPITAL	Adliya	Manama

Sponsors (1)

Lead Sponsor	Collaborator
Al Baraka Fertility Hospital

Country where clinical trial is conducted

Bahrain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pregnancy rate	B- HCG	2 weeks
Primary	clinical pregnancy rate	positive fetal heart beats	4 weeks